Thanks to a study recently published by a research team at MEPHI, Aix-Marseille Université, we have a highly plausible description of ivermectin’s mechanism of action against the SARS-CoV-2 spike protein.

In order to understand this mechanism, the reader must first understand that the SARS-CoV-2 Spike Protein Induces Hemagglutination—i.e., a reaction that causes clumping of red blood cells. A glycoprotein on the viral surface, namely hemagglutinin, interacts with red blood cells, leading to the clumping of red blood cells and the formation of a lattice.

As the Aix-Marseille team documents in their study: IVERMECTIN blocked HEMAGGLUTINATION when added to RED BLOOD CELLS prior to spike protein and reversed HEMAGGLUTINATION when added afterward.

By reversing the clumping of red blood cells, ivermectin enabled the dying patient’s proper respiratory function to return, thereby generating his or her astonishing recovery.

The results of these experiments were, first, that spike protein from these four lineages of SARS-CoV-2 induced hemagglutination (HA). Omicron induced HA at a significantly lower threshold concentration of spike protein than the three prior lineages and was much more electropositive on its central spike protein region. IVM blocked HA when added to RBCs prior to spike protein and reversed HA when added afterward. These results validate and extend prior findings on the role of glycan bindings of viral spike protein in COVID-19. They furthermore suggest therapeutic options using competitive glycan-binding agents such as IVM and may help elucidate rare serious adverse effects (AEs) associated with COVID-19 mRNA vaccines, which use spike protein as the generated antigen.